logo

CNTX

Context Therapeutics·NASDAQ
--
--(--)
--
--(--)
4.54 / 10
Netural

The fundamental assessment scores 4.5/10, pointing to average condition. Key positives include a healthy interest coverage ratio (15.48) and strong revenue growth (Total operating revenue YoY +78.47%, Operating revenue YoY +92.66%). Concerns arise from Days sales outstanding (72.55 days) and PB-ROE metrics. Net income-Revenue and Cash-MV are mid-range, while Asset-MV shows room for improvement. Overall, the fundamentals are selective rather than compelling.

Fundamental(4.54)SentimentTechnical

Analysis Checks(8/10)

Revenue-MV
Value-0.26
Score3/3
Weight17.37%
1M Return10.54%
Total operating revenue (YoY growth rate %)
Value78.47
Score2/3
Weight1.48%
1M Return1.11%
Days sales outstanding
Value72.55
Score1/3
Weight-1.91%
1M Return-1.57%
Profit-MV
Value0.46
Score2/3
Weight13.85%
1M Return8.45%
Net income-Revenue
Value-0.17
Score2/3
Weight13.86%
1M Return8.45%
PB-ROE
Value0.05
Score1/3
Weight16.86%
1M Return9.57%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.48
Score2/3
Weight-1.39%
1M Return-1.11%
Operating revenue (YoY growth rate %)
Value92.66
Score2/3
Weight0.57%
1M Return0.43%
Asset-MV
Value-0.50
Score3/3
Weight25.68%
1M Return13.15%
Cash-MV
Value-0.07
Score2/3
Weight13.62%
1M Return8.41%
Is CNTX undervalued or overvalued?
  • CNTX scores 4.54/10 on fundamentals and holds a Fair valuation at present. Backed by its -27.43% ROE, 0.00% net margin, -6.12 P/E ratio, 2.86 P/B ratio, and 72.73% earnings growth, these metrics solidify its Netural investment rating.